Shopping Cart
Remove All
Your shopping cart is currently empty
Cendakimab
😃Good
Catalog No. T76942Cas No. 2151032-62-9
Alias RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308
Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.
Cendakimab
Cendakimab
😃Good
Catalog No. T76942Alias RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308Cas No. 2151032-62-9
Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | In Stock | In Stock | |
| 5 mg | $463 | In Stock | In Stock | |
| 10 mg | $742 | - | In Stock | |
| 25 mg | $1,120 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:96% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis. |
| Targets&IC50 | IL-13α2:631 pM, aglycosylated IL-13:17 pM, IL-13Rα1:352 pM, glycosylated IL-13:37 pM |
| In vitro | Cendakimab is an IgG1k humanized monoclonal antibody that recognizes IL-13 and inhibits its binding to IL-13 receptor-specific subtypes (IL-13-Rα1 and IL-13-Rα2) with an IC50 of 352 pM and 631 pM, respectively, as determined by ELISA. [2] cendakimab inhibited glycosylated and non-glycosylated IL-13-induced STAT6 activity in a dose-dependent manner with IC50 of 37pM and 17pM, respectively. [1] |
| In vivo | In a mouse model of asthma, Cendakimab dose-dependent inhibited AHR (maximum inhibition 70.5%) and IL-13-dependent gene expression, and maximal inhibition of Muc5ac and AMCase activity was 70.7% and 54.2%, respectively. [2] |
| Synonyms | RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308 |
| Reactivity | Human |
| Verified Activity | Immobilized Human IL-13 Protein (His) at 2 μg/mL (30 μL/well) can bind Cendakimab. The EC50 is 0.002081μg/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-13 |
| Molecular Weight | 146.44 kDa |
| Cas No. | 2151032-62-9 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Cendakimab | purchase Cendakimab | Cendakimab cost | order Cendakimab | Cendakimab in vivo | Cendakimab in vitro | Cendakimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.